Compare · NVO vs RGNT
NVO vs RGNT
Side-by-side comparison of Novo Nordisk A/S (NVO) and Regentis Biomaterials Ltd. (RGNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RGNT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, NVO is down 34.2% and RGNT is down 57.5% - NVO leads by 23.3 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 1 for RGNT).
- NVO has more recent analyst coverage (25 ratings vs 0 for RGNT).
- Company
- Novo Nordisk A/S
- Regentis Biomaterials Ltd.
- Price
- $41.18+6.93%
- $3.10-0.32%
- Market cap
- $220.35B
- -
- 1M return
- +13.32%
- -22.31%
- 1Y return
- -34.24%
- -57.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2025
- News (4w)
- 5
- 1
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest RGNT
- Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
- SEC Form 3 filed by new insider Reske Galit
- SEC Form 3 filed by new insider Geller Ehud
- SEC Form 3 filed by new insider Valentine Keith
- SEC Form 3 filed by new insider Alpert Susan Phd Md
- SEC Form 3 filed by new insider Dykan Jeff
- SEC Form 3 filed by new insider Cohen-Arazi Efraim
- SEC Form 3 filed by new insider Gordashnikov Arie
- SEC Form 3 filed by new insider Gon Ori
- SEC Form 3 filed by new insider Ben-Elazar Pini